Anubhav Sahu

Principal Analyst

Moneycontrol Research

Why should investors look at Hikal?

BUSINESS

Why should investors look at Hikal?

One of the key aspects we like about Hikal is its efforts towards operational risk management

Laurus Labs: Foray into biotech adds new lever of growth; accumulate

BUSINESS

Laurus Labs: Foray into biotech adds new lever of growth; accumulate

Efforts to diversify will open up new opportunities for Laurus Labs and make it move towards a higher-margin trajectory

Galaxy Surfactants: Resilient business model affirms earnings visibility

BUSINESS

Galaxy Surfactants: Resilient business model affirms earnings visibility

The key thing to watch for Galaxy Surfactants is speciality portfolio’s growth prospects

Gland Pharma: Post IPO listing, what should investors do?

BUSINESS

Gland Pharma: Post IPO listing, what should investors do?

A vertically-integrated model and a strong regulatory compliance history with focus on R&D are tailwinds for Gland Pharma

HEG: Valuation below replacement cost

BUSINESS

HEG: Valuation below replacement cost

The spot price for needle coke -- the key raw material -- is around $1,800 per tonne. At this price, according to HEG, the industry should make decent margins

SRF: Diversification away from fluorochemicals to help sustain valuations

BUSINESS

SRF: Diversification away from fluorochemicals to help sustain valuations

The bulk of SRF's capex allocation in the medium term is dedicated to chemicals to gear up its capacity to meet the revival in demand in the next two to three years

Aurobindo Pharma: Leaner balance sheet and cash flows are bright spots

BUSINESS

Aurobindo Pharma: Leaner balance sheet and cash flows are bright spots

Key positives for Aurobindo Pharma are sustained performance in the anti-retroviral category and the traction in the US business

Aarti Industries Q2: long-term thesis of Make in India opportunity intact

BUSINESS

Aarti Industries Q2: long-term thesis of Make in India opportunity intact

Aarti Industries is projecting 15-20 percent earnings CAGR over the medium term

NOCIL Q2: ‘China plus’ sentiment aiding volume pick-up

BUSINESS

NOCIL Q2: ‘China plus’ sentiment aiding volume pick-up

Encouraged by the volume pick-up in Q2, NOCIL is confident of posting sales volume numbers in FY21 similar to FY20

Divi’s Labs: Improved growth visibility for custom synthesis, but valuation rich

BUSINESS

Divi’s Labs: Improved growth visibility for custom synthesis, but valuation rich

Divi's Labs result re-emphasise the fact that the global trend of de-risking supply chains away from China is adding to order enquires and product dispatches

IPCA Labs: Is vaccine anti-thesis to the pharma rally?

BUSINESS

IPCA Labs: Is vaccine anti-thesis to the pharma rally?

A key surprise is the IPCA's confidence in sustenance of EBITDA margin of 25-26 percent in H2 FY21 on the back of both subdued raw material prices and cost-saving measures

Gland Pharma IPO: Much more than a Heparin play; subscribe

BUSINESS

Gland Pharma IPO: Much more than a Heparin play; subscribe

Gland Pharma's IPO provides an opportunity to take exposure to a steady earnings compounder with strong credentials

Cipla: Covid opportunity and traction for Albuterol strong positives; accumulate

BUSINESS

Cipla: Covid opportunity and traction for Albuterol strong positives; accumulate

Cipla continues to be a significant pharma play during the pandemic because of its strong respiratory and a growing Covid portfolio

US elections: Political uncertainty puts onus on Federal Reserve to be on standby

BUSINESS

US elections: Political uncertainty puts onus on Federal Reserve to be on standby

At this critical point, the Federal Reserve has a crucial role to play to meet liquidity needs

Lupin: Covid opportunity strengthens US business

BUSINESS

Lupin: Covid opportunity strengthens US business

The possibility of positive developments on the product pipeline front and restructuring initiatives can accelerate earnings growth for Lupin

Sun Pharma: Traction in select speciality comes as a surprise

BUSINESS

Sun Pharma: Traction in select speciality comes as a surprise

Though valuation is still not inexpensive, we see improved trade sentiment for Sun Pharma post results. Sustained traction in speciality will be a key re-rating driver

Cadila Q2: Strong operational show backed by traction in COVID portfolio

BUSINESS

Cadila Q2: Strong operational show backed by traction in COVID portfolio

In the next three years, Cadila plans to launch 45 injectables, which are expected to generate revenue of USD 150-200 million at peak

Balaji Amines Q2: Import substitution play gets better with uplift in pharma

BUSINESS

Balaji Amines Q2: Import substitution play gets better with uplift in pharma

The new capex announcement for amine raw materials bridges a growing gap for Balaji Amines

Solara Active: Broadening of portfolio to be a re-rating catalyst

BUSINESS

Solara Active: Broadening of portfolio to be a re-rating catalyst

Solara is on the verge of transforming its business profile. It is looking at utilising cash flows to build project pipeline for CRAMS, investment behind technology platforms and looking for inorganic opportunities

Laurus Labs: Moves in to next growth orbit; accumulate

BUSINESS

Laurus Labs: Moves in to next growth orbit; accumulate

Laurus Labs has gained 3.6X since we recommended it in July 2019. What should you do now?

Apcotex Industries: Sustainable traction in demand for medical gloves is a key watch

BUSINESS

Apcotex Industries: Sustainable traction in demand for medical gloves is a key watch

Over the next 15 months, Apcotex will spend Rs 130-140 crore capex largely targeting XNBR factory capable of producing 40,000 tonnes annually

Navin Fluorine: CRAMS to aid near term growth guidance, stock fairly valued

BUSINESS

Navin Fluorine: CRAMS to aid near term growth guidance, stock fairly valued

Navin Fluorine's legacy businesses -refrigerants and inorganic fluoride businesses - are expected to remain lacklustre in the near term

Dr Reddy’s: Better US prospects to sustain valuations

BUSINESS

Dr Reddy’s: Better US prospects to sustain valuations

Dr Reddy's US growth prospects have improved after its recent settlement with Bristol Myers Squibb to launch an oncology drug

Paushak: Higher gross margins save the day

BUSINESS

Paushak: Higher gross margins save the day

Paushak is actively exploring opportunities like contract manufacturing with global customers and recently initiated such a business with a global agro major

Sections